» Articles » PMID: 31099725

An Immunoproteomic Approach to Identifying Immunoreactive Proteins in Amastigotes Using Sera of Dogs Infected with Canine Visceral Leishmaniasis

Overview
Date 2019 May 18
PMID 31099725
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Visceral leishmaniasis (VL), the most severe form of leishmaniasis, is caused by and . The infected dogs with canine visceral leishmaniasis (CVL) are important reservoirs for VL in humans, so the diagnosis, treatment and vaccination of the infected dogs will ultimately decrease the rate of human VL. Proteomics and immunoproteomics techniques have facilitated the introduction of novel drug, vaccine and diagnostic targets. Our immunoproteomic study was conducted to identify new immunoreactive proteins in amastigote form of . The strain of (MCAN/IR/07/Moheb-gh) was obtained from CVL-infected dogs. J774 macrophage cells were infected with the promastigotes. The infected macrophages were ruptured, and pure amastigotes were extracted from the macrophages. After protein extraction, two-dimensional gel electrophoresis was employed for protein separation followed by Western blotting. Western blotting was performed, using symptomatic and asymptomatic sera of the infected dogs with CVL. Thirteen repeatable immunoreactive spots were identified by Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Some, including prohibitin, ornithine aminotransferase, annexin A4, and apolipoprotein A-I, have been critically involved in metabolic pathways, survival, and pathogenicity of parasites. Further investigations are required to confirm our identified immunoreactive proteins as a biomarker for CVL.

Citing Articles

Recognition of Immunoreactive Proteins in Leishmania infantum Amastigote-Like and Promastigote Using Sera of Visceral Leishmaniasis Patients: a Preliminary Study.

Heidari S, Hajjaran H, Mohebali M, Akhoundi B, Gharechahi J Acta Parasitol. 2024; 69(1):533-540.

PMID: 38227109 DOI: 10.1007/s11686-023-00764-0.


The Defensive Interactions of Prominent Infectious Protozoan Parasites: The Host's Complement System.

Rashidi S, Mansouri R, Ali-Hassanzadeh M, Muro A, Nguewa P, Manzano-Roman R Biomolecules. 2022; 12(11).

PMID: 36358913 PMC: 9687244. DOI: 10.3390/biom12111564.


Mining the Proteome of Parasites Seeking Vaccine and Diagnostic Candidates.

Rashidi S, Sanchez-Montejo J, Mansouri R, Ali-Hassanzadeh M, Savardashtaki A, Bahreini M Animals (Basel). 2022; 12(9).

PMID: 35565525 PMC: 9099775. DOI: 10.3390/ani12091098.


Potential therapeutic targets shared between leishmaniasis and cancer.

Rashidi S, Fernandez-Rubio C, Manzano-Roman R, Mansouri R, Shafiei R, Ali-Hassanzadeh M Parasitology. 2021; 148(6):655-671.

PMID: 33536086 PMC: 10090780. DOI: 10.1017/S0031182021000160.

References
1.
Mutiso J, Macharia J, Kiio M, Ichagichu J, Rikoi H, Gicheru M . Development of Leishmania vaccines: predicting the future from past and present experience. J Biomed Res. 2013; 27(2):85-102. PMC: 3602867. DOI: 10.7555/JBR.27.20120064. View

2.
Jaiswal A, Khare P, Joshi S, Kushawaha P, Sundar S, Dube A . Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. PLoS One. 2014; 9(9):e108556. PMC: 4182492. DOI: 10.1371/journal.pone.0108556. View

3.
Furman D, Davis M . New approaches to understanding the immune response to vaccination and infection. Vaccine. 2015; 33(40):5271-81. PMC: 4581990. DOI: 10.1016/j.vaccine.2015.06.117. View

4.
Garin J, Diez R, Kieffer S, Dermine J, Duclos S, Gagnon E . The phagosome proteome: insight into phagosome functions. J Cell Biol. 2001; 152(1):165-80. PMC: 2193653. DOI: 10.1083/jcb.152.1.165. View

5.
Gafan C, Wilson J, Berger L, Berger B . Characterization of the ornithine aminotransferase from Plasmodium falciparum. Mol Biochem Parasitol. 2001; 118(1):1-10. DOI: 10.1016/s0166-6851(01)00357-7. View